Cerus Corporation (CERS)
CERS Stock Price Chart
Explore Cerus Corporation interactive price chart. Choose custom timeframes to analyze CERS price movements and trends.
CERS Company Profile
Discover essential business fundamentals and corporate details for Cerus Corporation (CERS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
31 Jan 1997
Employees
614.00
Website
https://www.cerus.comCEO
William M. Greenman
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS Financial Timeline
Browse a chronological timeline of Cerus Corporation corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 29 Oct 2025
EPS estimate is -$0.02, while revenue estimate is $55.12M.
Earnings released on 5 Aug 2025
EPS came in at -$0.03 falling short of the estimated -$0.02 by -50.00%, while revenue for the quarter reached $52.45M , missing expectations by -3.38%.
Earnings released on 1 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.05 by +20.00%, while revenue for the quarter reached $43.24M , missing expectations by -8.86%.
Earnings released on 20 Feb 2025
EPS came in at -$0.01 matching the estimated -$0.01, while revenue for the quarter reached $50.81M , missing expectations by -4.05%.
Earnings released on 30 Oct 2024
EPS came in at -$0.02 falling short of the estimated -$0.02 by -33.33%, while revenue for the quarter reached $46.02M , missing expectations by -9.21%.
Earnings released on 1 Aug 2024
EPS came in at -$0.03 falling short of the estimated -$0.02 by -25.00%, while revenue for the quarter reached $45.08M , missing expectations by -3.33%.
Earnings released on 2 May 2024
EPS came in at -$0.05 falling short of the estimated -$0.05 by -7.14%, while revenue for the quarter reached $38.37M , missing expectations by -6.75%.
Earnings released on 5 Mar 2024
EPS came in at -$0.01 falling short of the estimated -$0.01 by -58.23%, while revenue for the quarter reached $46.77M , missing expectations by -5.08%.
Earnings released on 2 Nov 2023
EPS came in at -$0.03 surpassing the estimated -$0.05 by +40.00%, while revenue for the quarter reached $39.77M , missing expectations by -22.35%.
Earnings released on 2 Aug 2023
EPS came in at -$0.07 falling short of the estimated -$0.05 by -40.00%, while revenue for the quarter reached $38.85M , missing expectations by -7.01%.
Earnings released on 4 May 2023
EPS came in at -$0.09 falling short of the estimated -$0.05 by -80.00%, while revenue for the quarter reached $30.97M , missing expectations by -11.07%.
Earnings released on 28 Feb 2023
EPS came in at -$0.08 falling short of the estimated -$0.05 by -68.42%, while revenue for the quarter reached $44.03M , missing expectations by -10.43%.
Earnings released on 3 Nov 2022
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $39.57M , missing expectations by -15.50%.
Earnings released on 4 Aug 2022
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $41.00M , missing expectations by -10.88%.
Earnings released on 5 May 2022
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $37.44M , missing expectations by -10.14%.
Earnings released on 22 Feb 2022
EPS came in at -$0.05 surpassing the estimated -$0.08 by +37.50%, while revenue for the quarter reached $39.87M , missing expectations by -9.18%.
Earnings released on 2 Nov 2021
EPS came in at -$0.07 surpassing the estimated -$0.10 by +30.00%, while revenue for the quarter reached $36.13M , missing expectations by -3.06%.
Earnings released on 3 Aug 2021
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $31.48M , missing expectations by -16.63%.
Earnings released on 4 May 2021
EPS came in at -$0.10 falling short of the estimated -$0.09 by -11.11%, while revenue for the quarter reached $23.38M , missing expectations by -11.04%.
Earnings released on 25 Feb 2021
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $28.20M , missing expectations by -16.05%.
Earnings released on 29 Oct 2020
EPS came in at -$0.08 surpassing the estimated -$0.12 by +33.33%, while revenue for the quarter reached $23.61M , missing expectations by -20.00%.
CERS Stock Performance
Access detailed CERS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.